OTCMKTS:RGRX RegeneRx Biopharmaceuticals (RGRX) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free RGRX Stock Alerts $0.0014 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.0014▼$0.001450-Day Range$0.00▼$0.0552-Week Range$0.00▼$8.80VolumeN/AAverage Volume172 shsMarket Capitalization$2,114.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get RegeneRx Biopharmaceuticals alerts: Email Address Ad DTIHere’s how to start a “Weekend Side Hustle” from your sofaHere’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.Weekend after weekend! About RegeneRx Biopharmaceuticals Stock (OTCMKTS:RGRX)RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.Read More RGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGRX Stock News HeadlinesNovember 5, 2023 | morningstar.comRegenerx Biopharmaceuticals Inc RGRXDOctober 31, 2023 | investing.comRegenerx Biopharm In (RGRXD)April 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.September 21, 2023 | businesswire.comLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater ChinaAugust 26, 2023 | seekingalpha.comRGRX RegeneRx Biopharmaceuticals, Inc.August 15, 2023 | finance.yahoo.comRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting ObligationsAugust 8, 2023 | finance.yahoo.comRegeneRx Receives Stockholder Approval for Reverse Stock SplitAugust 1, 2023 | finance.yahoo.comRegeneRx To Extend Consent Solicitation VoteApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.July 7, 2023 | thestreet.comBristol-Myers to Split Off Mead JohnsonMay 19, 2023 | thestreet.comPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage InitiationApril 13, 2023 | finance.yahoo.comFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259April 7, 2023 | marketwatch.comBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030April 7, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029March 1, 2023 | marketwatch.com2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028February 24, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 12, 2023 | finance.yahoo.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)January 31, 2023 | finance.yahoo.comThymosin Beta 4 Research Leads Toward Potential Future Anti-aging TherapyJanuary 27, 2023 | markets.businessinsider.com$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are BuyingJanuary 18, 2023 | marketwatch.comBiopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]January 17, 2023 | marketwatch.comBiopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the ReportJanuary 3, 2023 | finance.yahoo.comPublication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic KeratopathyNovember 18, 2022 | finance.yahoo.comBiopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic PartnershipsOctober 24, 2022 | finance.yahoo.comRegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye DiseaseSeptember 30, 2022 | investing.comClover Biopharmaceuticals Ltd (2197)September 27, 2022 | finance.yahoo.comRegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)See More Headlines Receive RGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:RGRX Previous SymbolOTC:RGRX CUSIPN/A CIK707511 Webwww.regenerx.com Phone(301) 208-9191Fax301-280-1996Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value($2.40) per share Price / Book0.00Miscellaneous Outstanding Shares1,510,000Free Float1,319,000Market Cap$2,114.00 OptionableNot Optionable Beta2.57 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Allan L. Goldstein Ph.D. (Age 86)Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board Comp: $86.54kMr. J. J. Finkelstein (Age 72)President, CEO & Director Comp: $75.26kKey CompetitorsWellness Center USAOTCMKTS:WCUIGenerex BiotechnologyOTCMKTS:GNBTAdhera TherapeuticsOTCMKTS:ATRXPropanc BiopharmaOTCMKTS:PPCBAmarantus BioScienceOTCMKTS:AMBSView All Competitors RGRX Stock Analysis - Frequently Asked Questions How have RGRX shares performed in 2024? RegeneRx Biopharmaceuticals' stock was trading at $0.0012 at the beginning of the year. Since then, RGRX stock has increased by 16.7% and is now trading at $0.0014. View the best growth stocks for 2024 here. When did RegeneRx Biopharmaceuticals' stock split? RegeneRx Biopharmaceuticals shares reverse split on Monday, August 14th 2023. The 1-100 reverse split was announced on Monday, August 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of RegeneRx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Palatin Technologies (PTN), Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA). How do I buy shares of RegeneRx Biopharmaceuticals? Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RGRX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RegeneRx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
